Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Investor Presentation (March 2025)
45 slides from Imricor Medical Systems's investor presentation, Mar 20, 2025
Slide 1: Equity Raising Presentation
For personal use only Equity Raising Presentation March 2025 Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Imricor Medical Systems, Inc. (IMR or Imricor) in connection with IMR’s not historical facts), including but not limited to, statements related to IMR’s financial performance, business strategy proposed capital raising (the Capital Raise), comprising
Slide 3: Disclaimer
Disclaimer Financial information advisers or any of their respective Beneficiaries. Investors should note that this presentation may contain unaudited financial information that has been prepared by To the maximum extent permitted by law, you agree to release and indemnify IMR, the Lead Manager and
Slide 4: Contents
Contents Investment Highlights 5 For personal use only The problem Imricor is solving 6-16 Market Opportunity 17 Looking ahead to 2025 22 Equity Raising Summary 26 Appendix 31 Investor Presentation,Capital September Capital 2021 Raise Presentation Raise Presentation 2025 || 44 2025
Slide 5: Investment Highlights
Investment Highlights Vision-MR Ablation Catheter (Consumable Revenue) For personal use only Strong Over US$130m World’s First & Active or FDA Approval Competitive invested to date Only Pending in 15 trial underway Position Technology MRI Compatible Hospitals Similar to Only MRI developed over Ablat
Slide 6: Cardiac Arrhythmias – A growing problem globally
Cardiac Arrhythmias – A growing problem globally Disturbances in the electrical impulses that maintain For personal use only a regular heart rhythm causes arrhythmias, that largely present as: • atrial flutter (AFL) • atrial fibrillation (Afib) • ventricular tachycardia (VT) Arrhythmias are a leadin
Slide 7: Treatment options
Treatment options 1 Ablation For personal use only • Catheter ablations have become first-line therapy for curing arrhythmias • Ablations can permanently restore the heart to normal rhythm • Minimally invasive surgery where a catheter is guided into the heart and energy is applied to destroy the hea
Slide 8: Catheter Ablation
Catheter Ablation For personal use only A catheter is guided into the heart and the physician will apply energy (radiofrequency, cryo, pulse field) through the catheter with the purpose of forming scars/lesions that destroy the heart cells responsible for causing the electrical misfiring. If the rig
Slide 9: X-Ray as an imaging modality
X-Ray as an imaging modality For personal use only X-rays are particularly good for visualizing bones and detecting fractures, dislocations, and bone density issues LIMITATIONS Soft Tissue Visualization X-rays are not as effective at visualizing soft tissues like muscles, ligaments, and organs. Radi
Slide 10: X-Ray guided cardiac ablation in conventional EP Lab
X-Ray guided cardiac ablation in conventional EP Lab In the past, doctors had to rely on X-Ray guidance as the only imaging modality available For personal use only CHALLENGES OF X-RAY Cannot visualize soft Cannot confirm lesions tissue of the heart created are durable Drives additional tool usage l
Slide 11: MRI as an imaging modality
MRI as an imaging modality For personal use only MRI is highly sensitive in detecting a variety of conditions, including tumours, brain disorders, spinal cord injuries, joint abnormalities, and vascular diseases. Detail MRI provides excellent contrast between different types of soft tissues, making
Slide 12: The Promise of MRI for Cardiac Interventions
The Promise of MRI for Cardiac Interventions Researchers from Johns Hopkins in the 1990’s and 2000’s demonstrated the benefits of performing ablations under MRI instead of X-Ray guidance. For personal use only The promise was for faster procedures, lower costs, higher first-time success rates all in
Slide 13: Imricor has pioneered this new approach over years
Imricor has pioneered this new approach over 19 years BENEFITS OF MRI For personal use only Superior soft tissue Lower cost, no need for ICE visualization in 3D catheter to guide septal crossing Faster procedures, no need Lower overall cost burden to map out the heart with on health system and expen
Slide 14: Imricor Enable Modern iCMR Labs
Imricor Enable Modern iCMR Labs • Imricor captures 100% of the consumable catheter revenue for each procedure For personal use only Capital equipment (Advantage-MR, 3rd party equip) Imricor iCMR lab (MRI scanner and lab room) MRI Partners Software Siemens (NorthStar) Philips Imricor GE Consumables (
Slide 15: Modern iCMR Lab Vendors
Modern iCMR Lab Vendors MRI COMPATIBLE EQUIPMENT NEEDED DEVELOPER IMRICOR REVENUE TYPE Ablation catheter Imricor Consumable For personal use only Diagnostic catheter Imricor Consumable Transseptal puncture kit Imricor Consumable Dispersive electrode Imricor Consumable Various sterile cables Imricor
Slide 16: Physician testimonial: Dr. Marco Götte
For personal use only “What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR” DR. MARCO GÖTTE Amsterdam University Medical Center Investor Investor Presentation, Presentation September 2021| 16 2025 | 16 Capital Raise Presentation
Slide 17: Market Opportunity
For personal use only Market Opportunity
Slide 18: iCMR Lab Economics: Hospital Labs
iCMR Lab Economics: Hospital For personal use only Labs X-ray and iCMR labs cost about the same to build: $3 million1 Procedures Procedure costs X-ray Lab iCMR Lab Annual benefit for iCMR3 AFL device costs $4,443 $4,000 $44,430 / yr VT device costs $9,618 $6,500 $311,800 / yr Afib device costs4 $9,6
Slide 19: iCMR Lab Economics: Imricor Revenue Opportunity
iCMR Lab Economics: US Top 50 Hospitals by volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 Imricor For personal use only Imricor ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital US$ $1.7m $1.1m $6.6m $9.43m Total Potential ATRIAL FLUTTER VT AFIB Revenue per H
Slide 20: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only CARDIAC ABLATION DISPOSABLES DRIVERS OF GLOBAL CATHETER MARKET: US, EU, ANZ ABLATION MARKET CATHETER SALES (USD M) Increased incid
Slide 21: Wide Geographical Spread
Wide Geographical Spread Imricor are approved for sale in over 30 countries, with 8 countries containing customer sites today For personal use only • Imricor’s products are currently approved in 31 countries, with 8 countries containing customer sites • Estimated over 1,000,000 ablation procedures a
Slide 22: Looking Ahead to 2025
Looking Ahead to 2025 For personal use only
Slide 23: How Imricor plans to change the standard of care
How Imricor plans to change the standard of care VISABL-VT will be the world’s first real-time iCMR guided VT ablation. For personal use only What to expect? A study1 in Barcelona of 84 patients, where CMR2 was utilised to guide VT procedures through pre-procedural image acquisition3, revealed the f
Slide 24: NorthStar – accelerating towards approval and commercialisation
NorthStar – accelerating towards approval and commercialisation For personal use only Key piece of the infrastructure, intended to be the central hub of every iCMR lab NorthStar Application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem for pediatric ho
Slide 25: Several key value drivers during 2025/26
Several key value drivers during 2025/26 For personal use only FDA Approval for US commercial release of platform technology • 510(k) submissions / approvals • VISABL-AFL clinical trial • PMA submissions / approvals First-in-human VT ablation guided by MRI • VISABL-VT clinical trial NorthStar 3D Map
Slide 26: Equity Raising Summary
Equity Raising Summary For personal use only
Slide 27: Equity Raising Summary
Equity Raising Summary Imricor Medical Systems is undertaking a Placement to professional and sophisticated investors utilising its capacity under ASX Listing Rules 7.1 and Offer Size and 7.1A (Institutional Placement or the Offer) to raise approximately A$70.0 million via the issue of approximate
Slide 28: Sources and Use of Funds
Sources and Use of Funds Sources of Funds A$m % SALES AND MARKETING For personal use only Placement proceeds 70.0 100.0% • Seeding of US Market with approval inside 12 months • Additional sales and clinical support following expected Total sources 70.0 100.0% demand after VT patient treatment • Incr
Slide 29: Equity Raising Timetable
Equity Raising Timetable Event Date For personal use only Institutional Placement bookbuild Wednesday, 19 March 2025 Placement Bookbuild closes 5.00pm Wednesday, 19 March 2025 Confirmation letters and CARD forms due 9.00am Thursday, 20 March 2025 Company resumes trading and announcement of completio
Slide 30: Questions?
For personal use only Questions?
Slide 31: Appendix
For personal use only Appendix
Slide 32: The problems we are solving through MRI-guided ablation procedures
The problems we are solving through MRI-guided ablation procedures PROCEDURE COST PROCEDURE VISUALISATION EFFECTIVENESS TIME SAFETY For personal use only • X-ray imaging provides • Visualisation limitations • Higher overall medical • Conventional 3D • Patient and doctor poor heart visualisation lead
Slide 33: Partners, Hospitals we Provide into and KOL Validation
Partners, Hospitals we Provide into and KOL Validation Our Partners PROF. GERHARD HINDRICKS DR. MARCO GÖTTE German Heart Center Amsterdam University of the Charité Medical Center For personal use only “With MRI-guided treatment of heart conditions, we are working “We are extremely excited to towards
Slide 34: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI For personal use only compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 21 is
Slide 35: FDA Global Pivotal Trial
FDA Global Pivotal Trial VISABL-AFL Trial – FDA Approval pathway Trial details For personal use only • Treatment of type 1 atrial flutter • Patients : 91 with possibility to end at 76 if primary endpoints are met (e.g. 80% acute success) • Participating hospitals : 4 • Expected FDA approval : 2H 202
Slide 36: MRI guided VT ablation - the most significant event in Imricor's history
For personal use only MRI guided VT ablation - the most significant event in Imricor's history VISABL-VT Trial – CE Mark Approval Pathway for 2nd Indication Trial details • Treatment of Ventricular Tachycardia • Patients : 64 • Participating hospitals : 2 • Comment: Trial data expected to stimulate
Slide 37: Imricor's Pipeline of Leading Tools for iCMR Labs
Imricor’s Pipeline of Leading Tools for iCMR Labs Current Products Future Products Our iCMR family of products are designed with patented technology to Products are developed and going through approvals to meet the needs of physicians and CVD patients around the world expand indications into VT and
Slide 38: Key Terms
Key Terms Vision-MR Ablation • Medical device developed by Imricor, designed for use within an MRI Catheter • World first, no competitors, all others only compatible with X-ray For personal use only • Irregular heartbeat, affects approximately 2% of US population • Expected to double to 4% of US pop
Slide 39: Imricor Leadership: Management
Imricor Leadership: Management For personal use only STEVE WEDAN JONATHON GUT GREGG STENZEL NICK CORKILL NICK TWOHY President and Chief Executive Officer, Vice President of Finance and Chief Chief Operating Officer Vice President Vice President of Marketing and Board Chair Financial Officer Corporat
Slide 40: Imricor Leadership: Board of Directors
Imricor Leadership: Board of Directors For personal use only STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL Jeffrey Leighton President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Officer, and Board Chair Independent Director Dr
Slide 41: Appendix 2) Key Risks
Appendix 2) Key Risks Regulatory: Imricor will, subject to regulatory clearances, seek to sell its key products in the European Union, the U.S., the Middle East, and Australia. Imricor is not assured of receiving future regulatory clearances and approvals for other indications or in other jurisdicti
Slide 42: Appendix 2) Key Risks
Appendix 2) Key Risks Reimbursement for Imricor’s products: Imricor expects its products will generally be purchased by hospitals and clinics who will then seek reimbursement from various public and private third-party payers once those products are used to provide health care services to patients.
Slide 43: Appendix 3) International Selling Restrictions
Appendix 3) International Selling Restrictions This document does not constitute an offer of CDIs in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the CDIs may not be offered or sold, in any country outside Australia except to
Slide 44: Appendix 3) International Selling Restrictions
Appendix 3) International Selling Restrictions New Zealand This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act"). The New CDIs are not being offered to the public within New Zealand other tha
Slide 45: Contact Information
Contact Information Investors & Australian Media: For personal use only Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.c
Imricor Medical Systems — Investor Presentation (March 2025) on 6ix